NORWELL, Mass., Aug. 29, 2025 (GLOBE NEWSWIRE) -- DIH Holding US, Inc. (“DIH” or the “Company”) (NASDAQ:DHAI) received a notice on August 26, 2025, from the Listing Qualifications Staff of The Nasdaq Stock Market LLC (“Nasdaq”), which stated that the Company was not in compliance with Nasdaq Listing Rule 5250(c)(1) because it had not filed its Report on Form 10-Q for the period ended June 30, 2025 (the “Form 10-Q”), and because the Company remains delinquent in filing its Form 10-K for the year ended March ...

Core Viewpoint - Aurora Spine Corporation reported strong financial results for Q2 2025, highlighting growth in revenue and operational performance, with a focus on advancing proprietary products in the minimally invasive spine surgery market [3][4][6]. Financial Performance - Q2 2025 revenues increased by 10.2% to $4.5 million, compared to $4.1 million in Q2 2024 [4][6]. - EBITDAC for Q2 2025 was $141,745, an improvement from $105,522 in Q2 2024 and a sequential increase from $(20,924) in Q1 2025 [4][9]. - Gross margin for Q2 2025 was 62.2%, slightly down from 62.4% in Q2 2024 but improved from Q1 2025 [7]. - Total operating expenses rose to $2.97 million in Q2 2025 from $2.74 million in Q2 2024, primarily due to increased sales commissions and marketing expenses [8]. Product Development and Market Strategy - The company achieved significant product milestones, with over 2,500 procedures using the SiLO™ SI Joint Fusion System and 1,500 surgeries using the DEXA-C™ implant [4]. - Sales of the DEXA-C cervical implant increased by 70% in the first half of 2025, totaling $794,000 compared to $467,000 in the same period in 2024 [4]. - The company is preparing to launch the Hydra A.E.R.O.™ facet fusion system, having built initial inventory and conducted successful initial surgeries ahead of schedule [4][5]. Market Challenges and Focus Areas - The company noted a decline in sales to the orthopedic and neurosurgical market, particularly in lumbar cage sales, which fell by 19% from the first half of 2024 to the same period in 2025 [4][6]. - Aurora Spine is focusing on improving its presence in the lumbar spine field and plans to launch the DEXA-L series in Q3 2025 [3][4].

Core Insights - Conavi Medical Corp. reported its financial results for the fiscal quarter ended June 30, 2025, highlighting significant developments in its product pipeline and financial position [1][11]. Business Highlights - The company completed successful validation testing of its next-generation Novasight™ system with leading interventional cardiologists, confirming its competitiveness with existing IVUS and OCT solutions [2][3]. - A $20 million financing round completed in April 2025 strengthens the company's balance sheet, providing resources for regulatory submission and production transition [6][8]. Regulatory and Production Milestones - Conavi is on track to submit its 510(k) application to the U.S. FDA in Q3 2025, which is crucial for its planned U.S. launch in the first half of 2026 [4][10]. - The transition of the Novasight system from development to manufacturing is underway, expected to align with the U.S. launch timeline [4]. Financial Performance - For Q3 FY 2025, the company recorded revenue of CAD 63,000, a decrease from CAD 401,000 in the same period the previous year [11]. - Operating expenses were CAD 4.7 million, down from CAD 8.8 million year-over-year, leading to a reduced operating loss of CAD 4.6 million compared to CAD 8.9 million in Q3 FY 2024 [12]. - The net loss for Q3 FY 2025 was CAD 3.6 million, or CAD 0.05 per share, significantly improved from a net loss of CAD 13.0 million, or CAD 2.12 per share, in the prior year [13]. Market Context - A publication in the Journal of the American College of Cardiology emphasizes the growing importance of intravascular imaging in treating complex coronary artery disease, indicating a favorable market environment for Conavi's hybrid imaging technology [2][5].

Core Insights - iRhythm Technologies, Inc. announced positive results from the AMALFI clinical trial, indicating that home-based screening with the Zio long-term continuous monitoring (LTCM) service significantly improved atrial fibrillation (AFib) detection and reduced time to diagnosis [1][5][6] Study Design and Population - The AMALFI trial was a randomized controlled trial involving 5,040 participants aged 65 and older with moderate to high stroke risk, comparing home-based screening using the Zio XT LTCM device to usual care over a follow-up period of 2.5 years [2][5] - Participants were identified through an automated search of electronic health records in 27 primary care practices in the UK, and the study was conducted entirely remotely without physical sites [2][6] Key Findings - The intervention group showed a higher rate of new AFib diagnoses (6.8%) compared to the control group (5.4%), with a statistically significant difference (p=0.03) [3][4] - The median time to diagnosis for the intervention group was 103 days, significantly shorter than the 530 days for the control group [3][4] - Participants in the intervention group had a longer average exposure to oral anticoagulation (1.63 months) compared to the control group (1.14 months), indicating improved treatment initiation [3] Implications for Healthcare - The study supports the feasibility of primary care-initiated, home-based diagnostic monitoring, aligning with the NHS's focus on disease prevention and early detection [4][6] - The findings suggest that the Zio LTCM service can be effectively implemented at scale, enhancing the identification of undiagnosed arrhythmias and enabling timely therapeutic interventions [7][8] Technology and Methodology - The Zio LTCM service utilizes a wearable ECG patch that captures continuous data for up to 14 days, processed by a deep-learned algorithm to detect various arrhythmias [6][7] - The service has been available in the US since 2008 and was introduced in the UK in 2014, demonstrating a commitment to improving patient outcomes through innovative technology [6][14]

来源：市场资讯 吴说获悉，Sharps Technology（纳斯达克代码：STSS）宣布完成逾 4 亿美元私募融资，并计划以 SOL 为核心资产，启动数字资产国库战略。若认股权证全部行使，募资总额或达 10 亿美元。公司还与 Solana 基金会签署非约束性协议，拟以 15% 折扣认购 5000 万美元 SOL。参与本轮融资的机构包括 Pantera、ParaFi、Monarq、FalconX 等。Sharps 表示将定期披露 SOL 持仓，并继续运营其医疗设备业 务。 （来源：吴说） ...

29 August 2025 | 9:33AM CST Eyebright (688050.SS): Earnings Review: 1H25 results in line, see premiumization trend and share gain in IOLs; Buy Eyebright reported 1H25 results on Aug 27, 2025. 1H25 revenue grew by 14.7% (-1.3% vs. GSe), and net profits were in-line at Rmb213mn (+2.5% yoy, -4.4% vs. GSe). IOL sales grew by 8.2% yoy in 1H25 (including PIOL product per company breakdown) despite industry cataract surgery volume decrease, implying that Eyebright continues to gain share and sees continuing premiu ...

28 August 2025 | 2:58PM CST Mindray (300760.SZ): Earnings review: 1H25 miss on faster channel inventory destocking; guides for a turning point in Q3; Buy Mindray reported 1H25 results on Aug 27, 2025. 1H25 revenue decreased by 18.4% (-7.4% vs. GSe), where we saw both China revenue (-33.4% yoy) and overseas revenue (+5.4% yoy) were lower-than-expected mainly due to 1) China's channel inventory destocking in 2Q25 despite strong procurement activities; and 2) weaker performance in patient monitor and life supp ...

Core Viewpoint - Picard Medical, Inc. has announced the pricing of its initial public offering (IPO), aiming to raise $17 million through the sale of 4,250,000 shares at $4.00 per share, with trading expected to commence on August 29, 2025 under the ticker symbol "PMI" [1][3]. Group 1: Offering Details - The IPO consists of 4,250,000 shares priced at $4.00 each, totaling gross proceeds of $17 million before expenses [1]. - Underwriters have an option to purchase an additional 637,500 shares within 30 days to cover over-allotments [1]. - The offering is being conducted on a firm commitment basis, with WestPark Capital, Inc. as the Lead Manager and Sole Bookrunner [2]. Group 2: Use of Proceeds - Proceeds from the IPO will support market expansion in China through a joint venture, fund research and development for new products, and enhance sales and marketing capabilities [3]. - The funds will also be used to repay debt and cover general operational expenses and working capital [3]. Group 3: Company Background - Picard Medical, Inc. is the parent company of SynCardia Systems, LLC, which manufactures the SynCardia Total Artificial Heart (STAH), the only FDA and Health Canada approved total artificial heart [6]. - The STAH is the most widely used artificial heart globally, with over 2,100 implants performed in 27 countries [6].

AUDUBON, Pa., Aug. 28, 2025 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal technology company, announced that a Delaware jury has returned a verdict in favor of Globus in its patent infringement litigation against Life Spine, Inc. The jury found that Life Spine’s Prolift family of implants infringed several claims of a valid Globus patent and awarded Globus both lost profits and reasonable royalty damages. The technology at issue involves expandable spinal fusion implants, ...

Q2’25 revenue of $12.1 million, 99% YOY growth Full year revenue guidance of $45.5M - $47.5M CARLSBAD, Calif., Aug. 28, 2025 (GLOBE NEWSWIRE) -- Carlsmed, Inc. (Nasdaq: CARL) (“Carlsmed” or the “Company”), a medical technology company pioneering AI-enabled personalized spine surgery solutions, today reported financial results for the second quarter ended June 30, 2025. “Our strong commercial performance was driven by the continued adoption of our highly differentiated AI-enabled aprevo® technology platform ...